Background
==========

Both COPD and tuberculosis (TB) are leading causes of morbidity and mortality in developing countries.[@b1-copd-13-375],[@b2-copd-13-375] The two diseases not only share common risk factors such as smoking and poor socioeconomic status, but also coexist and interact in disease development and manifestation.[@b1-copd-13-375]--[@b3-copd-13-375] Although pulmonary TB (PTB) has been identified as a risk factor for COPD,[@b4-copd-13-375] and several studies have found an association between previous PTB and higher COPD prevalence,[@b5-copd-13-375]--[@b7-copd-13-375] few studies have explored the clinical and radiological features of COPD in patients with previous PTB.

The chronic inflammatory response and long-term anatomic alterations induced by PTB were believed to be the main pathological basis for the impairment of lung function and poor prognosis.[@b8-copd-13-375] TB-associated structural alterations, such as scar formation, bronchial stenosis, and bronchiectasis,[@b9-copd-13-375] affect both the development of COPD and disease manifestation, which may have unique features compared with COPD without previous PTB. Recently, radiological phenotypes of COPD have received much attention, and the presence of pulmonary emphysema, bronchial wall thickening, and bronchiectasis have been proposed as the 3 main morphological findings likely to provide relevant information about different phenotypes of COPD.[@b10-copd-13-375] Interestingly, both emphysema and bronchiectasis were associated with PTB.

Therefore, we set out to explore whether the prevalence, distribution, and severity of emphysema and bronchiectasis are different, and associated with clinical features in COPD patients with radiological signs of previous PTB. Our results showed that compared with those without PTB, COPD patients with previous PTB demonstrated more prevalent and severe bronchiectasis, and the unique distribution of emphysema, which was associated with significant dyspnea and higher frequency of severe exacerbations.

Materials and methods
=====================

Study subjects
--------------

Patients with stable COPD visiting Beijing Tongren Hospital, Capital Medical University from July 2008 to July 2016 were evaluated. The diagnosis of COPD was based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria,[@b4-copd-13-375] as used in our previous study. These were as follows:[@b11-copd-13-375] 1) age \>40 years, 2) history of smoking (smoking index \>10 pack-year) and/or exposure to biomass fuel (mostly coal or wood burning stoves)/chemical agents/noxious particles for \>10 years, 3) chronic cough with or without wheeze for \>3 months in each year for 2 consecutive years, and 4) irreversible obstructive dysfunction defined as postbronchodilator forced expiratory volume in 1 second (FEV~1~)/forced vital capacity (FVC) \<70% on spirometry. Patients were excluded if they met any of the following conditions: receiving therapy of systemic corticosteroids or other immunosuppressive agents in the preceding 8 weeks; with allergic bronchopulmonary mycosis, interstitial lung diseases, active PTB, autoimmune diseases, and severe heart failure; doctor-diagnosed asthma or bronchiectasis before diagnosis of COPD; and previous PTB resulting in severe lung damage ("destroyed lung"), since "destroyed lung" per se could lead to severe impairment of lung functions, restrictive and/or obstructive, which could not be differentiated from COPD.

Definition of previous PTB
--------------------------

Previous PTB was defined as present if discrete linear or reticular fibrotic scars, or dense nodules with distinct margins were identified within the upper lobes and/or superior segment of lower lobes on computed tomography (CT) scan, with or without calcification of the lesions and/or local lymph nodes.[@b11-copd-13-375]--[@b13-copd-13-375] A distinct history of TB was not necessary for the determination.

Lung high-resolution computed tomography (HRCT) and evaluation of bronchiectasis and emphysema
----------------------------------------------------------------------------------------------

Chest HRCT was performed with a 64-row, multiple detector CT scanner (Philips Company, Amsterdam, the Netherlands). The presence, extent (Smith score), severity (Bhalla score) and types (classified into cylindric, cystic, or mixed) of bronchiectasis, as well as the presence, severity (Goddard score) and types (classified into centrilobular, panlobular, paraseptal, and bullae) of emphysema were evaluated by 2 radiologists experienced in the interpretation of HRCT and blinded to the patients' clinical data. The radiologists finished the evaluations independently and differences in the readings were resolved by their final consensus.[@b11-copd-13-375]

Bronchiectasis was determined to be present if HRCT showed bronchial wall thickening with the ratio of the diameter of bronchus to that of the accompanying pulmonary artery being \>1.1 (signet ring sign) or the lack of tapering of bronchi (tramline sign).[@b14-copd-13-375] The extent of bronchiectasis was scored for each pulmonary lobe, with the lingula as a separate lobe. The grading system proposed by Smith et al[@b15-copd-13-375] was adopted in our study. According to this system, the absence of bronchiectasis was scored as 0, bronchiectasis in \<25% of bronchi as 1, in 25% to 49% of bronchi as 2, in 50% to 74% as 3, and in ≥75% as 4. The total score ranged from 0 to 24 points. Patients with a score ≤1 were considered as normal, since mild bronchiectasis only visible in a single pulmonary segment may exist in a significant percentage of healthy population.[@b11-copd-13-375],[@b16-copd-13-375] The type of bronchiectasis was identified as cylindric, cystic, or mixed (varicose) according to the morphological characteristics of the dilated bronchi.[@b14-copd-13-375] The severity of bronchiectasis in each lobe was graded by the Bhalla scoring system on a scale of 0 to 3,[@b17-copd-13-375],[@b18-copd-13-375] with 0 for no involvement; 1 for mild, with luminal diameter slightly greater than that of adjacent blood vessel; 2 for moderate, with lumen 2--3 times that of adjacent vessel; and 3 for severe, with lumen 3 times that of adjacent vessel.

The presence and the type of emphysema were visually assessed for each lobe, with the lingula as a separate lobe. Emphysema was classified into centrilobular, panlobular (panacinar), paraseptal, and bullous as previously reported.[@b14-copd-13-375] With the presence scored as 1 and the absence scored as 0, a semi-quantitative method, with scores of both lungs ranging from 0 to 6, was adopted to show the extent of a certain type of emphysema. The severity of emphysema was visually evaluated with the modified Goddard scoring system.[@b19-copd-13-375],[@b20-copd-13-375] Six images were analyzed in 3 slices (including the aortic arch, carina, and 1--2 cm above the highest hemidiaphragm) of both lungs, and a total score of all images was considered as a representative value of the severity of emphysema for each patient. Each image was classified as normal (score 0), 5% affected (score 0.5), 25% affected (score 1), 50% affected (score 2), 75% affected (score 3), and \>75% affected (score 4); therefore, the total score of each patient ranged from 0 to 24 points.

Pulmonary function tests
------------------------

Spirometry (JAEGER, MasterScreen-body + diffusion + APS, Hoechberg, Germany) was performed to determine the lung function measurements and bronchodilator reversibility as we previously reported.[@b11-copd-13-375] Post-bronchodilator FEV~1~/FVC% and FEV~1~ were measured 15 minutes after the inhalation of 400 µg salbutamol.

Definition of respiratory symptoms and exacerbations
----------------------------------------------------

Chronic cough and expectoration were considered to be present if the symptoms lasted for more than 3 consecutive months. Exertional dyspnea was identified as present if the mMRC (modified Medical Research Council Questionnaire) score was ≥1. The duration of a symptom such as dyspnea was defined as the length of time from its onset to enrollment of the patient in the study, as we previously described.[@b11-copd-13-375] Frequency of acute exacerbation (AE) was defined based on the number of times the patient was hospitalized or presented for emergency visits because of AE during the year before enrollment.

Bacterial culture of sputum samples
-----------------------------------

Results of sputum cultures were reviewed retrospectively and positive results for bacteria, especially *Pseudomonas aeruginosa*, were compared between groups as described previously.[@b11-copd-13-375] The sputum samples were obtained when the patients experienced a severe exacerbation. Sputum samples were acceptable if they contained fewer than 10 squamous epithelial cells and more than 25 leukocytes per low-powered field.[@b11-copd-13-375],[@b17-copd-13-375]

Analysis
--------

The prevalence, distribution, and severity of emphysema and bronchiectasis on HRCT, and the clinical characteristics were compared between COPD patients with and without previous PTB. To explore whether the potential effect of previous PTB on emphysema and bronchiectasis was localized or extensive, we also compared the presence and the severity of emphysema and bronchiectasis between the lung with TB sequelae and the contralateral lung in patients with TB sequelae in a single lung.

The statistical package SPSS version 17.0 (SPSS, Chicago, IL, USA) was used for statistical analysis. Data were expressed as mean ± SD. Independent-samples *t*-Test (for normal distribution parameters) and Mann--Whitney *U*-test (for abnormal distribution parameters) were adopted for comparisons of continuous data between the 2 groups. Comparisons of continuous data among 3 groups were performed by analysis of variance test (for normal distribution) or Kruskal--Wallis test (for abnormal distribution). Categorical variables between different groups were analyzed by *χ*^2^ test. *p*-values \<0.05 were considered as statistically significant. As for multiple comparisons among 3 or 4 groups (including *χ*^2^ test or Kruskal--Wallis test), *p*-values \<0.017 or *p*-values \<0.008, respectively, were taken as statistically significant.

Results
=======

Clinical characteristics and chest CT features of subjects with COPD
--------------------------------------------------------------------

During the study period, 231 patients with COPD were consecutively enrolled. These included 156 males (67.5%) and 75 females (32.5%) with a mean age of 76.8 years, and a majority of them were smokers (82.2%). The GOLD spirometry classification ranged from 2 to 4, with 83 patients (35.9%) in GOLD 2, 109 (47.2%) in GOLD 3, and 39 (16.9%) in GOLD 4. Data are shown in [Table 1](#t1-copd-13-375){ref-type="table"}.

Signs of previous PTB were found by chest HRCT in 104 patients (104/231, 45.0%), of whom only 42 (42/231, 18.2%) had a definite history of PTB and had received anti-TB therapy. TB sequelae in the upper lobes were found in most of the patients (99/104, 95.2%). As for the symptoms, the average time course of chronic cough/expectoration and that of exertional dyspnea were 19.1 and 6.28 years, respectively. *P. aeruginosa* was found positive in the sputum of 15 patients with COPD, and 13 of them had coexistent bronchiectasis on CT ([Table 1](#t1-copd-13-375){ref-type="table"}).

Bronchiectasis on HRCT was found in 50.6% (117/231) of the COPD patients. With regard to the sites of bronchiectasis, the middle lobes/lingular segments (64.1%, *p*=0.018), and the lower lobes (68.3%, *p*=0.002) were involved more often compared with the upper lobes (48.7%). No statistical difference was found in the Smith score among upper lobes, middle lobes/lingular segments, and lower lobes (3.45, 3.96, and 4.02, respectively, *p*=0.321). Among COPD patients with comorbid bronchiectasis (COPD-Bx, n=117), most showed mild bronchiectasis (Bhalla score =1), and only 6.8% (8/117) of them had a Bhalla score ≥2. The majority (115/117, 98.3%) of the COPD-Bx subjects demonstrated cylindric bronchiectasis, and mixed (varicose) type was found in only 4 patients (4/117, 3.4%), with no patients showing typical cystic bronchiectasis ([Table 2](#t2-copd-13-375){ref-type="table"}).

Emphysema on HRCT was found in 62.3% (144/231) of COPD patients. With regard to the sites of emphysema, the upper lobes (92.4%) were involved more often compared with the middle lobes/lingular segments (68.7%), and the lower lobes (63.1%); both *p*\<0.001. In addition, a significant difference was found in the severity of emphysema (Goddard score) among the upper, middle, and lower lobes (overall *p*=0.015). The Goddard score of the upper lobes was found to be significantly higher than that of the lower lobes (*p*=0.006). With regard to the types of emphysema, centrilobular emphysema was the most common (42%, 97/231), followed by panlobular (34.6%, 80/231), bullous (26.8%, 62/231), and paraseptal emphysema (19.9%, 46/231). According to the semi-quantitative evaluation, the distribution of centrilobular or panlobular emphysema was found to be more extensive than that of paraseptal or bullae emphysema (2.76 vs 1.71 and 2.76 vs 1.90, 2.93 vs 1.71 and 2.93 vs 1.90, respectively, all the *p*-values \<0.001) ([Table 2](#t2-copd-13-375){ref-type="table"}).

Clinical characteristics of COPD patients with previous PTB
-----------------------------------------------------------

No statistical difference was found in age, gender, smoking status, body mass index, maintenance medication, FEV~1~% predicted, and GOLD grading between COPD patients with and without previous infection of PTB. However, patients with previous PTB showed a longer history of dyspnea (7.31 vs 5.44 years), more severe dyspnea (mMRC: 2.63 vs 2.33; mMRC ≥2: 85.6% vs 74.0%), a higher frequency of exacerbation in the previous year (1.56 vs 1.09), and a higher positive rate of *P. aeruginosa* by sputum culture (12.5% vs 1.6%) ([Table 1](#t1-copd-13-375){ref-type="table"}).

Characteristics of bronchiectasis in COPD patients with previous PTB
--------------------------------------------------------------------

The percentage of patients with CT bronchiectasis was higher in those with previous PTB (64.4%) compared with those without PTB (39.4%, *p*\<0.001). The difference was more significant when the upper lobes were compared (62.7% vs 30.0%, *p*\<0.001) ([Table 2](#t2-copd-13-375){ref-type="table"}, [Figures 1](#f1-copd-13-375){ref-type="fig"} and [3](#f3-copd-13-375){ref-type="fig"}). Coexisting upper lobe bronchiectasis was found in 42.4% (42/99) of patients with PTB sequelae in upper lobes, but in only 11.8% (15/127) of patients without PTB sequelae (*p*\<0.001). For patients with bronchiectasis, the Smith score tended to be higher in those with previous PTB (n=67) compared with those without (n=50), though the difference was not significant. The severity of bronchiectasis was identified as mild (Bhalla score =1) and cylindric for most of the patients in the 2 groups, but more severe (Bhalla score ≥2) or varicose bronchiectasis was found only in COPD patients with previous PTB ([Table 2](#t2-copd-13-375){ref-type="table"}).

Presence and characteristics of bronchiectasis were also compared between the lung with TB sequelae and the contralateral lung in patients with TB sequelae limited to a single lung (n=65). The prevalence of bronchiectasis in the TB-involved lung, especially the upper lobe, was significantly higher (*p*\<0.01) compared with the contralateral lung ([Table 3](#t3-copd-13-375){ref-type="table"}, [Figures 1](#f1-copd-13-375){ref-type="fig"} and [3](#f3-copd-13-375){ref-type="fig"}), but no difference was found in the severity of bronchiectasis ([Table 3](#t3-copd-13-375){ref-type="table"}).

Characteristics of emphysema in COPD patients with previous PTB
---------------------------------------------------------------

The prevalence of emphysema between patients with and without previous PTB showed no significant difference (67.3% vs 58.2%). Interestingly, in patients with previous PTB, more had emphysema of the middle lobes/lingular segments (81.4% vs 56.7%, *p*=0.001) and of the lower lobes (72.8% vs 54.1%, *p*=0.019), compared with those without PTB, but no difference was found in the upper lobe emphysema. The severity score of emphysema (Goddard score) in patients with previous PTB was higher than that in patients without PTB (7.88 vs 6.17, *p*=0.028). Patients with previous PTB also demonstrated a statistically higher prevalence of panlobular emphysema (43.2% vs 27.5%, *p*=0.013) and bullae (32.7% vs 22%, *p*=0.069). The distribution of centrilobular emphysema in patients with PTB was more extensive than that in patients without PTB (3.12 vs 2.40, *p*=0.039) ([Table 2](#t2-copd-13-375){ref-type="table"}).

Presence and characteristics of emphysema were also compared between the lung with TB sequelae and the contralateral lung in patients with TB sequelae limited to a single lung (n=65). Interestingly, no significant difference was seen in the prevalence, severity, and type of emphysema between the 2 lungs of the same patients. ([Table 3](#t3-copd-13-375){ref-type="table"}, [Figures 2](#f2-copd-13-375){ref-type="fig"} and [3](#f3-copd-13-375){ref-type="fig"}).

Discussion
==========

In this cross-sectional study of the chest imaging (bronchiectasis and emphysema) and clinical features of COPD with previous PTB, the most important finding was that, compared with those without PTB, COPD patients with previous PTB showed higher prevalence and more severe bronchiectasis, increased prevalence of lower lung emphysema, and more extensive emphysema, which were evident in lobes near the local sequelae of PTB and both the lungs, and this could not be explained only by the local effects of TB. Studies have shown that even localized PTB might be a risk factor for COPD,[@b9-copd-13-375],[@b14-copd-13-375],[@b21-copd-13-375] suggesting a role beyond its local effects. Our results provide new data to support the implication of PTB in the development and/or manifestation of COPD associated with cigarette smoking or biomass fuel exposure.

CT bronchiectasis, mostly mild-to-moderate in degree, and found in as high as 57.2% of COPD patients, was associated with exacerbations, poor lung function, and even mortality from the disease.[@b17-copd-13-375] The potential mechanisms underlying the development of bronchiectasis in COPD are poorly understood. Our recent study showed that previous PTB was an independent risk factor for coexistent bronchiectasis in COPD,[@b11-copd-13-375] suggesting that PTB might be a cause of bronchiectasis in these patients. In the current study, we found that previous PTB was associated with more prevalent and severe bronchiectasis, which was more evident in the TB-involved lung, indicating local airway damage induced by TB infection.

Another interesting finding of our study was the association of previous PTB with higher prevalence of lower lung emphysema and more severe emphysema of both lungs, characterized by more extensive centrilobular emphysema, and higher prevalence of panlobular emphysema and bullae. The association of PTB with emphysema was observed as early as the 1950s. These earlier studies found increased incidence of obstructive ventilatory dysfunction by lung function testing,[@b22-copd-13-375],[@b23-copd-13-375] and of emphysema by chest X-ray,[@b24-copd-13-375],[@b25-copd-13-375] although the latter was not consistently confirmed by pathological studies.[@b26-copd-13-375] The advent of HRCT made the observation and classification of emphysema easier and more accurate, but few studies have been carried out to re-examine the association of PTB with emphysema using HRCT in cross-sectional, or ideally, longitudinal studies. Our results warrant further studies to elucidate the effect of PTB on the development of emphysema, particularly in the context of cigarette smoke or biomass fuel exposure.

The potential effect of TB on the development of COPD was believed to be mediated by mechanisms of chronic inflammation.[@b27-copd-13-375]--[@b29-copd-13-375] Chronic inflammatory response may persist in patients with TB even after the microbiological cure.[@b30-copd-13-375] Radovic et al[@b31-copd-13-375] demonstrated that after 6 months of anti-TB treatment, serum markers of systemic inflammation such as erythrocyte sedimentation rate and fibrinogen decreased significantly, but were still abnormally high.[@b31-copd-13-375] As early as 1960s, Hennes et al[@b32-copd-13-375] showed that antibodies reacting with extracts of human lungs were present in the serum of many patients with PTB and idiopathic obstructive emphysema, suggesting that tubercle bacilli might serve as an "endogenous Freund adjuvant" stimulating antibody response to damaged tissue.[@b32-copd-13-375] Recently, Tang et al[@b33-copd-13-375] found that serum concentrations of cytokines such as soluble interleukin-2 receptor (sIL-2R), IL-6 and tumor necrosis factor (TNF-α) in COPD patients with TB were higher than those without TB or those with TB but without COPD,[@b33-copd-13-375] suggesting that COPD combined with TB may result in excessive inflammation. Studies on airway or lung inflammation, such as with bronchoalveolar lavage (BAL), in patients with PTB showed that expressions of matrix metalloproteinases (MMPs) such as matrix metalloproteinase-1, -3 and -9 (MMP-1, MMP-3 and MMP-9), which played important roles in tissue destruction, were significantly upregulated when compared with normal or symptomatic controls.[@b34-copd-13-375],[@b35-copd-13-375] BAL concentrations of proinflammatory cytokines such as TNF-α, IL-6 and IL-8, were also found to be correlated with the HRCT score in active pulmonary TB.[@b36-copd-13-375] However, the features of airway/lung inflammation in COPD patients with previous PTB need to be clarified further.

Previous PTB in COPD patients was also clinically relevant as these patients complained of more significant dyspnea and had more severe exacerbations. In our study, no significant difference was found in spirometry measurements (FEV~1~/FVC and FEV~1~% predicted) between COPD patients with or without PTB, which was similar to the results of Yakar et al.[@b37-copd-13-375] Given that FEV~1~ correlated poorly with symptoms, impairment of a patient's quality of life, and exacerbations,[@b4-copd-13-375] this result could be explained, at least partially, by the presence of more prevalent and severe bronchiectasis and emphysema.[@b11-copd-13-375],[@b18-copd-13-375],[@b38-copd-13-375] Other results of clinical relevance include the finding that positive culture of *P. aeruginosa* in sputum was seen mostly in COPD patients with prior PTB, which could be explained by the presence of more severe bronchiectasis in this group of patients. Therefore, in COPD patients with prior PTB, especially those with coexistent bronchiectasis, regular sputum surveillance for *P. aeruginosa*, and strategies for eradication of the pathogen may be useful for prevention of COPD exacerbations. Because previous PTB was also associated with unique features of emphysema, interventional treatments such as volume reduction may need special consideration; for example, in volume reduction surgery, COPD patients with prior PTB may experience less post-treatment pneumothorax due to pleural adhesions.

It should be noted that, in our study, typical TB sequelae on chest CT was the only criterion for the diagnosis of prior PTB in the majority of our patients. This diagnostic criterion has been used in several studies,[@b11-copd-13-375]--[@b13-copd-13-375] especially in high TB-burden countries.[@b9-copd-13-375],[@b37-copd-13-375],[@b39-copd-13-375] However, prior PTB cannot be completely excluded if no TB sequelae are found by chest X-ray or CT. Our study also has several limitations. Because of the cross-sectional design of the study, the time sequence of the occurrence of PTB and emphysema and/or bronchiectasis cannot be determined, and therefore, a cause--effect relationship cannot be obtained. No evaluation of the interaction between PTB and cigarette smoke was attempted, though the smoking status of the TB group and the non-TB group of our patients was similar. We believe that this interaction would be very important for understanding the potential effect of PTB in COPD.

Conclusion
==========

We have found in a well-defined cohort of COPD patients that those with previous PTB had more prevalent and severe bronchiectasis and emphysema on HRCT, which were associated with significant dyspnea and higher frequency of severe exacerbations. Although PTB may have a local effect on bronchiectasis, its involvement in airspace damage of COPD may be extensive. Further prospective studies of larger sample size are warranted to clarify the effects and mechanisms of PTB on the development or progression of COPD, particularly in the context of cigarette smoking.
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![Bronchiectasis in case 1 with TB sequelae in RUL (HRCT).\
**Abbreviations:** TB, tuberculosis; RUL, right upper lobe; HRCT, high-resolution CT, computed tomography.](copd-13-375Fig1){#f1-copd-13-375}

![Similar emphysema at LUL and RUL in case 2 with TB sequelae in RUL (HRCT).\
**Abbreviations:** LUL, left upper lobe; RUL, right upper lobe; TB, tuberculosis; HRCT, high-resolution CT.](copd-13-375Fig2){#f2-copd-13-375}

![Extensive emphysema and mild bronchiectasis in case 3 with TB sequelae at RUL (HRCT).\
**Notes:** (**A**) upper level; (**B**) middle level; (**C**) lower level.\
**Abbreviations:** TB, tuberculosis; RUL, right upper lobe; HRCT, high-resolution CT.](copd-13-375Fig3){#f3-copd-13-375}

###### 

Baseline and clinical characteristics of subjects with COPD, with and without PTB

  Parameter                                             COPD           COPD with previous TB   COPD without previous TB   *p*-value
  ----------------------------------------------------- -------------- ----------------------- -------------------------- -----------
  Subjects, n (%)                                       231            104 (45.0)              127 (55.0)                 
  Male, n (%)                                           156 (67.5)     73 (70.2)               83 (65.4)                  0.435
  Age, (years)                                          76.8 (9.4)     77.5 (9.4)              76.1 (9.3)                 0.247
  Smoking status                                                                                                          
   Present smokers, n (%)                               68 (29.4)      29 (27.9)               39 (30.7)                  0.823
   Former smokers, n (%)                                122 (52.8)     55 (52.9)               67 (52.8)                  
   Non-smokers, n (%)                                   41 (17.7)      20 (19.2)               21 (16.5)                  
  Pack-years smoked                                     42.6 (25.3)    45.3 (26.4)             40.5 (24.4)                0.187
  Body mass index, (kg/m^2^)                            23.2 (4.77)    22.8 (4.33)             23.6 (5.08)                0.186
  History of chronic cough/sputum, (years)              19.1 (12.3)    20.1 (12.2)             18.3 (12.5)                0.182
  History of dyspnea, (years)                           6.28 (5.70)    7.31 (6.19)             5.44 (5.13)                **0.008**
  Daily treatments, n (%)                                                                                                 
   Anticholinergic                                      160 (69.2)     69 (66.3)               91 (71.6)                  0.384
   Long-acting β adrenergic                             143 (61.9)     62 (59.6)               81 (63.7)                  0.517
   ICS                                                  143 (61.9)     62 (59.6)               81 (63.7)                  0.517
  mMRC                                                  2.46 (1.15)    2.63 (1.16)             2.33 (1.13)                **0.045**
  mMRC ≥2, n (%)                                        183 (79.2)     89 (85.6)               94 (74.0)                  **0.031**
  Exacerbations in the previous year                    1.30 (1.27)    1.56 (1.39)             1.09 (1.12)                **0.011**
  Hemoglobin, (g/L)                                     125.1 (17.1)   124.8 (16.3)            125.4 (17.8)               0.783
  FEV~1~/FVC, %                                         0.46 (0.11)    0.45 (0.10)             0.47 (0.11)                0.252
  FEV~1~% predicted                                     0.43 (0.13)    0.41 (0.12)             0.44 (0.14)                0.215
  GOLD grading, n (%)                                                                                                     
   Grade II                                             83 (35.9)      37 (35.6)               46 (36.3)                  0.987
   Grade III                                            109 (47.2)     49 (47.1)               60 (47.2)                  
   Grade IV                                             39 (16.9)      18 (17.3)               21 (16.5)                  
  Location of PTB sequelae                                                                                                
   Upper lobes, n (%)                                                  99 (95.2)               0 (0)                      
   Middle lobes, n (%)                                                 2 (1.92)                0 (0)                      
   Lower lobes, n (%)                                                  8 (7.69)                0 (0)                      
  Positive culture of bacteria, n (%)                   53 (22.9)      29 (27.9)               24 (18.9)                  0.106
  Positive culture of *Pseudomonas aeruginosa*, n (%)   15 (6.5)       13 (12.5)               2 (1.6)                    **0.001**

**Notes:** *p*-values represent the comparisons between COPD patients with TB and those without. Lingular segment of left lung was taken as "middle lobe" of left lung. Continuous data are expressed as mean (standard deviation), Categorical data are expressed as number (percentage). The statistically significance values *p*\<0.05 shown in bold.

**Abbreviations:** PTB, pulmonary tuberculosis; TB, tuberculosis; ICS, inhaled corticosteroids; mMRC, modified Medical Research Council Questionnaire; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

CT characteristics of bronchiectasis and emphysema of subjects with COPD, with and without PTB

  Parameters                                                             COPD (n=231)   COPD with previous TB (n=104)   COPD without previous TB (n=127)   *p*-value
  ---------------------------------------------------------------------- -------------- ------------------------------- ---------------------------------- -----------
  Bronchiectasis prevalence, n (%)                                       117 (50.6)     67 (64.4)                       50 (39.4)                          **0.000**
   Upper lobes, n (%)                                                    57 (48.7)      42 (62.7)                       15 (30.0)                          **0.000**
   Middle lobes, n (%)                                                   75 (64.1)      45 (67.2)                       30 (60.0)                          0.424
   Lower lobes, n (%)                                                    80 (68.3)      42 (62.6)                       38 (76.0)                          0.126
  Smith score[a](#tfn3-copd-13-375){ref-type="table-fn"}                 6.97 (5.81)    7.78 (6.29)                     5.90 (4.96)                        0.162
   Upper lobes                                                           3.45 (2.05)    3.73 (2.66)                     2.66 (1.23)                        0.194
   Middle lobes                                                          3.96 (2.31)    4.06 (2.31)                     3.80 (2.32)                        0.541
   Lower lobes                                                           4.02 (2.31)    4.31 (2.34)                     3.71 (2.26)                        0.246
  Bhalla score[b](#tfn4-copd-13-375){ref-type="table-fn"}                                                                                                  
   1, n (%)                                                              109 (93.2)     59 (88.0)                       50 (100.0)                         **0.031**
   ≥2, n (%)                                                             8 (6.8)        8 (11.9)                        0 (0)                              
  Bronchiectasis type                                                                                                                                      
   Cylindric                                                             115 (98.3)     65 (97.0)                       50 (100)                           
   Cystic                                                                0 (0)          0 (0)                           0 (0)                              
   Varicose                                                              4 (3.4)        4 (5.9)                         0 (0)                              
  Emphysema prevalence, n (%)                                            144 (62.3)     70 (67.3)                       74 (58.2)                          0.158
   Upper lobes, n (%)                                                    133 (92.4)     67 (95.7)                       66 (89.1)                          0.141
   Middle lobes, n (%)                                                   99 (68.7)      57 (81.4)                       42 (56.7)                          **0.001**
   Lower lobes, n (%)                                                    91 (63.1)      51 (72.8)                       40 (54.1)                          **0.019**
  Goddard score[a](#tfn3-copd-13-375){ref-type="table-fn"}               7.00 (5.66)    7.88 (5.51)                     6.17 (5.71)                        **0.028**
   Upper levels                                                          3.57 (2.28)    3.59 (2.26)                     3.56 (2.33)                        0.940
   Middle levels                                                         2.92 (1.89)    2.82 (1.81)                     3.05 (2.00)                        0.684
   Lower levels                                                          2.68 (1.88)    2.95 (1.99)                     2.33 (1.69)                        0.120
  Types of emphysema, prevalence                                                                                                                           
   Centrilobular, n (%)                                                  97 (42.0)      49 (47.1)                       48 (37.8)                          0.153
   Panlobular, n (%)                                                     80 (34.6)      45 (43.2)                       35 (27.5)                          **0.013**
   Paraseptal, n (%)                                                     46 (19.9)      24 (23.0)                       22 (17.3)                          0.276
   Bullae, n (%)                                                         62 (26.8)      34 (32.7)                       28 (22.0)                          0.069
  Types of emphysema, score[a](#tfn3-copd-13-375){ref-type="table-fn"}                                                                                     
   Centrilobular                                                         2.76 (1.59)    3.12 (1.71)                     2.40 (1.39)                        **0.039**
   Panlobular                                                            2.93 (1.71)    2.78 (1.67)                     3.14 (1.76)                        0.322
   Paraseptal                                                            1.71 (0.88)    1.71 (0.80)                     1.73 (0.98)                        0.943
   Bullae                                                                1.90 (1.11)    1.94 (1.07)                     1.86 (1.17)                        0.518

**Notes:**

Smith score, Goddard score, and semi-quantitative score of different types of emphysema represent the means of patients with bronchiectasis, or with emphysema, or with a certain type of emphysema.

Defined based on the highest Bhalla score of the patient. Lingular segment of the left lung was taken as "middle lobe" of the left lung. *p*-values represent the comparisons between COPD patients with TB and those without. Continuous data are expressed as mean (standard deviation), Categorical data are expressed as number (percentage). The statistically significance values *p*\<0.05 shown in bold.

**Abbreviations:** PTB, pulmonary tuberculosis; TB, tuberculosis.

###### 

Bronchiectasis and emphysema of 2 lungs in 65 patients with TB sequelae in a single lung

  Parameters                                                       TB sequelae involved lung                                 Contralateral lung                                                                                                                                                        
  ---------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------- ------------- --------------------------------------------------------- ------------- ------------- ------------- -------------
  Bronchiectasis prevalence, n (%)                                 25 (38.5)[\*\*](#tfn7-copd-13-375){ref-type="table-fn"}   21 (32.3)[\*](#tfn6-copd-13-375){ref-type="table-fn"}   20 (30.8)     39 (60.0)[\*\*](#tfn7-copd-13-375){ref-type="table-fn"}   7 (10.8)      10 (15.4)     13 (20.0)     20 (30.8)
  Smith score[a](#tfn8-copd-13-375){ref-type="table-fn"}           2.36 (1.03)                                               2.86 (1.01)                                             2.96 (0.94)   4.56 (3.15)                                               2.71 (1.25)   2.90 (1.19)   2.49 (1.08)   4.02 (3.32)
  Bhalla score,[b](#tfn9-copd-13-375){ref-type="table-fn"} n (%)                                                                                                                                                                                                                                       
   1                                                               25 (100)                                                  20 (95.2)                                               18 (90.0)     36 (92.3)                                                 7 (100)       7 (70.0)      12 (92.3)     17 (85.0)
   ≥2                                                              0 (0)                                                     1 (4.8)                                                 2 (10.0)      3 (7.7)                                                   0 (0)         3 (30.0)      1 (7.7)       3 (15.0)
  Emphysema prevalence, n (%)                                      35 (53.8)                                                 23 (35.4)                                               30 (46.2)     39 (60.0)                                                 32 (49.2)     21 (32.3)     28 (43.1)     35 (53.8)
   Centrilobular                                                   21 (32.3)                                                 7 (10.8)                                                13 (20.0)     25 (38.5)                                                 18 (27.7)     10 (15.4)     13 (20.0)     21 (32.3)
   Panlobular                                                      17 (26.2)                                                 9 (13.8)                                                14 (21.5)     25 (38.5)                                                 13 (20.0)     5 (7.7)       13 (20.0)     19 (29.2)
   Paraseptal                                                      3 (4.6)                                                   5 (7.7)                                                 5 (7.7)       12 (18.5)                                                 4 (6.2)       4 (6.2)       3 (4.6)       8 (12.3)
   Bullae                                                          10 (15.4)                                                 6 (9.2)                                                 7 (10.8)      17 (26.2)                                                 9 (13.8)      3 (4.6)       5 (7.7)       13 (20.0)
  Goddard score[a](#tfn8-copd-13-375){ref-type="table-fn"}                                                                                                                                         4.28 (2.70)                                                                                         4.20 (2.71)

**Notes:**

Compared with "contralateral lung", *p*\<0.05;

Compared with "contralateral lung", *p*\<0.01;

Smith score and Goddard score represent the means of patients with bronchiectasis, or with emphysema;

defined based on the highest Bhalla score of the patient. Lingular segment of left lung was taken as the "middle lobe" of the left lung. Continuous data are expressed as mean (standard deviation); Categorical data are expressed as number (percentage).

**Abbreviation:** TB, tuberculosis.
